Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

AGM Statement

23 Jul 2019 07:00

RNS Number : 3337G
Scapa Group PLC
23 July 2019
 

 

 

 

 

23 July 2019

 

LEI No. 213800QIPVTK5ES5UU36

 

 

Scapa Group plc

AGM Statement

 

 

Scapa Group plc (AIM: SCPA) is holding its Annual General Meeting at 10:30am today. At the meeting, Larry Pentz, Chairman of Scapa Group, will provide the following update.

 

The Group's trading performance for the first quarter is in line with the Board's expectations.

 

Q1 Statutory Basis

Q1 Continuing Basis1

Organic (excl Syst2 & CVT3)

Growth (Reported)

Growth (constant FX)

Growth (Reported)

Growth (constant FX)

Growth (Reported)

Growth (constant FX)

Healthcare Revenues

47.8%

41.5%

40.6%

34.6%

7.9%

3.5%

Industrial Revenues

4.5%

2.8%

4.5%

2.8%

4.5%

2.8%

Scapa Group Revenues

21.6%

18.4%

18.7%

15.6%

5.6%

3.1%

 

The integration and consolidation projects are proceeding according to plan and the Company continues to seek additional opportunities to deliver long-term sustainable growth.

 

The Board considers Scapa to be well positioned to make further progress against its strategic objectives and remains confident in the Group's outlook.

 

1 Excluding IFRS 15 provision release. A contract liability provision was created as a result of the acquisition of Systagenix in line with the requirements of IFRS 15 and this is excluded on a 'continuing' basis as it represents a non-cash item. This provision will be released on a straight-line basis over a five-year period, in line with the exclusive supply contract

² Systagenix

³ ConvaTec

 

For further information:

 

Scapa Group plc

Heejae Chae - Group Chief Executive

Oskar Zahn - Chief Financial Officer

 

Tel: 0161 301 7430

Numis Securities Limited

(Nominated Adviser/Joint Broker)

 

Mark Lander, Richard Thomas

Tel: 020 7260 1000

Berenberg

(Joint Broker)

 

Chris Bowman, Toby Flaux

 

Tel: 020 3207 7800

FTI Consulting

(Media Relations)

 

Brett Pollard, Victoria Foster Mitchell

Tel: 020 3727 1000

 

 

About Scapa Group plc

Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

 

Healthcare

Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

 

For further information, please visit www.scapahealthcare.com

 

Industrial

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

 

For further information, please visit www.scapaindustrial.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMPGUGGMUPBGQP
Date   Source Headline
2nd Jul 20184:33 pmRNSTotal Voting Rights
28th Jun 20184:12 pmRNSDirector/PDMR Shareholding
5th Jun 20184:00 pmRNSDirector/PDMR Shareholding
31st May 201810:31 amRNSTotal Voting Rights
30th May 201810:20 amRNSDirector/PDMR Shareholding
22nd May 20187:00 amRNSFinal Results
30th Apr 201810:30 amRNSTotal Voting Rights
12th Apr 20187:00 amRNSTrading Statement
11th Apr 20183:29 pmRNSIncident at Dunstable Site
29th Mar 201811:48 amRNSTotal Voting Rights
26th Mar 20187:00 amRNSAcquisition
28th Feb 20181:38 pmRNSTotal Voting Rights
7th Feb 20189:17 amRNSBlock listing Interim Review
31st Jan 20189:08 amRNSTotal Voting Rights
25th Jan 20182:14 pmRNSBlock listing Interim Review
8th Jan 201810:10 amRNSDirectorate Change
7th Dec 20173:52 pmRNSDirector/PDMR Shareholding
7th Dec 20173:49 pmRNSAdditional Listing
29th Nov 201711:15 amRNSDirector/PDMR Shareholding
28th Nov 20172:56 pmRNSDirector/PDMR Shareholding
28th Nov 20172:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20179:36 amRNSDirector/PDMR Shareholding
21st Nov 20177:00 amRNSHalf-year Report
17th Nov 201710:22 amRNSAdditional Listing
11th Oct 20177:00 amRNSTrading Statement
4th Oct 20177:00 amRNSCapital Markets Day
26th Sep 201711:38 amRNSAdditional Listing
21st Sep 20174:21 pmRNSHolding(s) in Company
8th Sep 201711:31 amRNSDirector/PDMR Shareholding
4th Sep 20173:18 pmRNSDirector/PDMR Shareholding
4th Sep 201710:13 amRNSAdditional Listing
25th Aug 20177:00 amRNSDirector/PDMR Shareholding
17th Aug 20174:14 pmRNSDirector/PDMR Shareholding
11th Aug 20174:12 pmRNSDirector/PDMR Shareholding
9th Aug 20177:00 amRNSAcquisition
7th Aug 20171:56 pmRNSBlock listing Interim Review
25th Jul 201710:09 amRNSBlock listing Interim Review
19th Jul 20179:29 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSAGM Statement
1st Jun 20171:59 pmRNSHolding(s) in Company
30th May 20172:09 pmRNSAdditional Listing
23rd May 20177:00 amRNSFinal Results
18th May 20173:47 pmRNSHolding(s) in Company
17th May 20173:36 pmRNSHolding(s) in Company
3rd May 201710:31 amRNSAdditional Listing
21st Apr 20179:41 amRNSHolding(s) in Company
19th Apr 20173:33 pmRNSAdditional Listing
13th Apr 20177:00 amRNSTrading Statement
27th Mar 20172:05 pmRNSDirector/PDMR Shareholding
23rd Mar 201711:46 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.